메뉴 건너뛰기




Volumn 389, Issue 10088, 2017, Pages 2448-2449

Immune oncology in hepatocellular carcinoma—hype and hope

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; REGORAFENIB; SORAFENIB; TICILIMUMAB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

EID: 85018638275     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31044-9     Document Type: Note
Times cited : (14)

References (11)
  • 1
    • 57349191046 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet, JM, Ricci, S, Mazzaferro, V, et al., for SIS Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 3
    • 85007560261 scopus 로고    scopus 로고
    • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): a randomised, double-blind, placebo-controlled, phase 3 trial
    • Bruix, J, Qin, S, Merle, P, for the Investigators R group. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (2017), 56–66.
    • (2017) Lancet , vol.389 , pp. 56-66
    • Bruix, J.1    Qin, S.2    Merle, P.3
  • 4
    • 84984564079 scopus 로고    scopus 로고
    • Global patterns of hepatocellular carcinoma management from diagnosis to death: the bridge study
    • Park, JW, Chen, M, Colombo, M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the bridge study. Liver Int 35 (2015), 2155–2166.
    • (2015) Liver Int , vol.35 , pp. 2155-2166
    • Park, J.W.1    Chen, M.2    Colombo, M.3
  • 5
    • 84949112760 scopus 로고    scopus 로고
    • Immunological landscape and immunotherapy of hepatocellular carcinoma
    • Prieto, J, Melero, I, Sangro, B, Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 12 (2015), 681–700.
    • (2015) Nat Rev Gastroenterol Hepatol , vol.12 , pp. 681-700
    • Prieto, J.1    Melero, I.2    Sangro, B.3
  • 6
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok, JD, Kluger, H, Callahan, MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
    • (2013) N Engl J Med , vol.369 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 7
    • 84879141840 scopus 로고    scopus 로고
    • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    • Sangro, B, Gomez-Martin, C, de la Mata, M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.
    • (2013) J Hepatol , vol.59 , pp. 81-88
    • Sangro, B.1    Gomez-Martin, C.2    de la Mata, M.3
  • 8
    • 85007494451 scopus 로고    scopus 로고
    • Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
    • Duffy, AG, Ulahannan, SV, Makorova-Rusher, O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66 (2017), 545–551.
    • (2017) J Hepatol , vol.66 , pp. 545-551
    • Duffy, A.G.1    Ulahannan, S.V.2    Makorova-Rusher, O.3
  • 9
    • 85018660134 scopus 로고    scopus 로고
    • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
    • published online April 20
    • El-Khouiery, AB, Sangro, B, Yau, T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017 published online April 20 http://dx.doi.org/10.1016/S0140-6736(17)31046-2.
    • (2017) Lancet
    • El-Khouiery, A.B.1    Sangro, B.2    Yau, T.3
  • 10
    • 84992497184 scopus 로고    scopus 로고
    • Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis
    • Wang, H, Liu, A, Bo, W, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis. Dig Liver Dis 48 (2016), 1275–1282.
    • (2016) Dig Liver Dis , vol.48 , pp. 1275-1282
    • Wang, H.1    Liu, A.2    Bo, W.3
  • 11
    • 84982913900 scopus 로고    scopus 로고
    • Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features
    • Calderaro, J, Rousseau, B, Amaddeo, G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 64 (2016), 2038–2046.
    • (2016) Hepatology , vol.64 , pp. 2038-2046
    • Calderaro, J.1    Rousseau, B.2    Amaddeo, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.